Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Teneligliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 20/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Teneligliptin SCHEMBL17270067 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9PTGS2HRH1 | |
| Teneligliptin SCHEMBL17270087 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9PTGS2HRH1 | |
| Teneligliptin SCHEMBL161778 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9PTGS2HRH1 | |
| Teneligliptin SCHEMBL16451097 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP9PTGS2HRH1 | |
| Teneligliptin SCHEMBL2711577 | 0.99 | DPP4 (0.98) | DPP4DPP8DPP9PTGS2HRH1 | |
| Teneligliptin SCHEMBL2142591 | 0.99 | DPP4 (0.98) | DPP4DPP8DPP9PTGS2HRH1 | |
| Teneligliptin SCHEMBL14634647 | 0.99 | DPP4 (0.98) | DPP4DPP8DPP9PTGS2HRH1 | |
| Teneligliptin SCHEMBL17065851 | 0.99 | DPP4 (0.98) | DPP4DPP8DPP9PTGS2HRH1 | |
| Teneligliptin SCHEMBL17065852 | 0.99 | DPP4 (0.98) | DPP4DPP8DPP9PTGS2HRH1 | |
| Teneligliptin SCHEMBL17065854 | 0.98 | DPP4 (1.00) | DPP4DPP8DPP9PTGS2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310396-A1 | THIAZOLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | ZHU HONGWEN (US) | 2013-11-21 | — | — | US | claimed |
| WO-2012099915-A1 | THIAZOLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | ZHU HONGWEN (US) | 2012-07-26 | — | — | WO | claimed |
| JP-2012500190-A | — | — | 2012-01-05 | — | — | JP | claimed |
| EP-2326326-A2 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2011-06-01 | — | — | EP | claimed |
| WO-2010018217-A2 | ORGANIC COMPOUNDS FOR WOUND HEALING | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | WO | claimed |
| WO-2021151251-A1 | TREATING TREATMENT-RESISTANT DIABETES WITH GLUCOKINASE ACTIVATOR | HUA MEDICINE (SHANGHAI) LTD. (CN) | 2021-08-05 | — | — | WO | disclosed |
| US-20130310396-A1 | THIAZOLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | ZHU HONGWEN (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2012099915-A1 | THIAZOLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | ZHU HONGWEN (US) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310396-A1 | THIAZOLIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | SLC5A2, SLC5A1, DPP4 | DPP4 3/4885DPP8 13/4885DPP9 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.